These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 39372417)

  • 1. The multifaceted roles of B lymphocytes in metabolic dysfunction-associated steatotic liver disease.
    Li H; Xia N
    Front Immunol; 2024; 15():1447391. PubMed ID: 39372417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis.
    Fu JT; Liu J; Wu WB; Chen YT; Lu GD; Cao Q; Meng HB; Tong J; Zhu JH; Wang XJ; Liu Y; Zhuang C; Sheng C; Shen FM; Liu X; Wang H; Yu Y; Zhang Y; Liang HY; Zhang JB; Li DJ; Li X; Wang ZB; Wang P
    J Hepatol; 2024 Sep; 81(3):389-403. PubMed ID: 38670321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).
    Bruzzì S; Sutti S; Giudici G; Burlone ME; Ramavath NN; Toscani A; Bozzola C; Schneider P; Morello E; Parola M; Pirisi M; Albano E
    Free Radic Biol Med; 2018 Aug; 124():249-259. PubMed ID: 29920340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom.
    Kuchay MS; Isaacs S; Misra A
    Diabetes Metab Syndr; 2024 May; 18(5):103034. PubMed ID: 38714040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular RECK as a Critical Regulator of Metabolic Dysfunction-associated Steatohepatitis Development.
    Dashek RJ; Cunningham RP; Taylor CL; Alessi I; Diaz C; Meers GM; Wheeler AA; Ibdah JA; Parks EJ; Yoshida T; Chandrasekar B; Rector RS
    Cell Mol Gastroenterol Hepatol; 2024; 18(3):101365. PubMed ID: 38797477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
    Vacca M; Kamzolas I; Harder LM; Oakley F; Trautwein C; Hatting M; Ross T; Bernardo B; Oldenburger A; Hjuler ST; Ksiazek I; Lindén D; Schuppan D; Rodriguez-Cuenca S; Tonini MM; Castañeda TR; Kannt A; Rodrigues CMP; Cockell S; Govaere O; Daly AK; Allison M; Honnens de Lichtenberg K; Kim YO; Lindblom A; Oldham S; Andréasson AC; Schlerman F; Marioneaux J; Sanyal A; Afonso MB; Younes R; Amano Y; Friedman SL; Wang S; Bhattacharya D; Simon E; Paradis V; Burt A; Grypari IM; Davies S; Driessen A; Yashiro H; Pors S; Worm Andersen M; Feigh M; Yunis C; Bedossa P; Stewart M; Cater HL; Wells S; Schattenberg JM; Anstee QM; ; Tiniakos D; Perfield JW; Petsalaki E; Davidsen P; Vidal-Puig A
    Nat Metab; 2024 Jun; 6(6):1178-1196. PubMed ID: 38867022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Muddle. MASLD and MASH on the Horizon.
    Meagher T
    J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A
    Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.